Xianquan Zhan

Xianquan Zhan

Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Central South University

Affiliated withCentral South UniversityShandong First Medical University & Shandong Academy of Medical Science

Research Area

Biography

Xianquan Zhan received his M.D. and Ph.D. training in preventive medicine at West China University of Medical Sciences during 1989-1999. He received his post-doctoral training in oncology and cancer proteomics at Central South University and University of Tennessee Health Science Center (UTHSC). He worked at UTHSC and Cleveland Clinic in USA during 2001-2012, and achieved the rank of Associate Professor at UTHSC. In 2012, he moved to Central South University Xiangya Hospital as a Professor, and Advisors of MS/PhD graduate students and postdoctoral fellows. He is also the Fellow of Royal Society of Medicine, Fellow of EPMA, European EPMA National Representative, AAAS member, Editor-In-Chief of IJCDT, Execute Editor-in-Chief of Med One, Associate Editors of EPMA Journal and BMC Medical Genomics, and Guest Editors of Frontiers in Endocrinology (IF = 3.65) and Mass Spectrometry Reviews (IF = 9.068). He has published 130 articles, 16 book chapters, 3 books, and 2 US patents in the field of clinical proteomics and biomarkers. His research interests focus on the development and use of multi-omics (genomics, transcriptomics, proteomics, metabolomics, and radiomics) and systems biology to study cancer mechanisms, and discover effective biomarker pattern for predictive, preventive, and personalized medicine (PPPM) or precission medicine (PM) in cancer, and also focus on cancer proteoforms and post-translational modifications (PTMs).

JoVE Journal Publications

ArticleTotal : 3
Year
Two-dimensional Gel Electrophoresis Coupled with Mass Spectrometry Methods for an Analysis of Human Pituitary Adenoma Tissue Proteome
Publication title

Cited by 18

2018
2019
2026

Other Publications

Article
Year
Comparative proteomics analysis of human lung squamous carcinoma.

Biochemical and biophysical research communications| PubMed ID: 12943690

2003
2003
2012
Proteomic and bioinformatics analyses of mouse liver microsomes.

International journal of proteomics| PubMed ID: 22500222

2012
2012
2013
[Effect of DJ-1 siRNA on biological behavior of human lung squamous carcinoma SK-MES-1 cells].

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences| PubMed ID: 23406859

2013
Pituitary adenoma nitroproteomics: current status and perspectives.

Oxidative medicine and cellular longevity| PubMed ID: 23533694

2013
2013
2013
Mass spectrometry analysis of nitrotyrosine-containing proteins.

Mass spectrometry reviews| PubMed ID: 24318073

2015
VE-statin/Egfl7 expression in malignant glioma and its relevant molecular network.

International journal of clinical and experimental pathology| PubMed ID: 24696719

2014
VE-statin/Egfl7 siRNA inhibits angiogenesis in malignant glioma in vitro.

International journal of clinical and experimental pathology| PubMed ID: 24696724

2014
2014
2014
2015
2015
2015
Nitroproteins in Human Astrocytomas Discovered by Gel Electrophoresis and Tandem Mass Spectrometry.

Journal of the American Society for Mass Spectrometry| PubMed ID: 26450359

2015
2016
Human Pituitary Adenoma Proteomics: New Progresses and Perspectives.

Frontiers in endocrinology| PubMed ID: 27303365

2016
Editorial: Systems Biological Aspects of Pituitary Tumors.

Frontiers in endocrinology| PubMed ID: 27445988

2016
2017
2017
2017
2017
2018
2018
2018
2018
2018
2018
2019
The MAPK Pathway-Based Drug Therapeutic Targets in Pituitary Adenomas.

Frontiers in endocrinology| PubMed ID: 31231308

2019
2019
2019
2019
2019
2019
2021
HSP60 Regulates Lipid Metabolism in Human Ovarian Cancer.

Oxidative medicine and cellular longevity| PubMed ID: 34557266

2021
2022
2022
Editorial: Biomolecular modifications in endocrine-related cancers.

Frontiers in endocrinology| PubMed ID: 36714076

2023
Editorial: New molecular targets involved in lung adenocarcinoma.

Frontiers in endocrinology| PubMed ID: 36755924

2023
2023
2023
2023
2023
2023
Personalized Drug Therapy: Innovative Concept Guided With Proteoformics.

Molecular & cellular proteomics : MCP| PubMed ID: 38354979

2024
2024
2024
2024
2025
2025
2025
2025
Proteoformics: Current status and future perspectives.

Journal of proteomics| PubMed ID: 40834981

2025
2025
2026